MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592882 | Name: Amustaline HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Amustaline Dihydrochloride treatment inactivates high levels of Zika virus in red blood cell components.

Chemical Structure

Amustaline HCl
Amustaline HCl
CAS#210584-54-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 592882

Name: Amustaline HCl

CAS#: 210584-54-6 (HCl)

Chemical Formula: C22H27Cl4N3O2

Exact Mass:

Molecular Weight: 507.28

Elemental Analysis: C, 52.09; H, 5.37; Cl, 27.95; N, 8.28; O, 6.31

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
210584-54-6 (HCl) 220180-88-1 (free base) 212335-58-5 878189-87-8 (free base)
Synonym
Amustaline Dihydrochloride; Amustaline HCl; S 303 dihydrochloride; S 303 HCl; S 303; S-303; S303.
IUPAC/Chemical Name
beta-Alanine, N-9-acridinyl-, 2-(bis(2-chloroethyl)amino)ethyl ester, dihydrochloride
InChi Key
WEOLKSYHLNAIRH-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H25Cl2N3O2.2ClH/c23-10-13-27(14-11-24)15-16-29-21(28)9-12-25-22-17-5-1-3-7-19(17)26-20-8-4-2-6-18(20)22;;/h1-8H,9-16H2,(H,25,26);2*1H
SMILES Code
O=C(OCCN(CCCl)CCCl)CCNC1=C(C=CC=C2)C2=NC3=CC=CC=C31.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 507.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sow C, Laughhunn A, Girard YA, Lanteri MC, Amar El Dusouqui S, Stassinopoulos A, Grellier P. Inactivation of Plasmodium falciparum in whole blood using the amustaline and glutathione pathogen reduction technology. Transfusion. 2020 Apr;60(4):799-805. doi: 10.1111/trf.15734. Epub 2020 Mar 4. PMID: 32129497; PMCID: PMC7187285. 2: North AK, Mufti N, Sullivan T, Corash L. Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione. Transfusion. 2020 Feb;60(2):358-366. doi: 10.1111/trf.15662. Epub 2020 Jan 12. PMID: 31930533; PMCID: PMC7027779. 3: Aydinok Y, Piga A, Origa R, Mufti N, Erickson A, North A, Waldhaus K, Ernst C, Lin JS, Huang N, Benjamin RJ, Corash L. Amustaline-glutathione pathogen- reduced red blood cell concentrates for transfusion-dependent thalassaemia. Br J Haematol. 2019 Aug;186(4):625-636. doi: 10.1111/bjh.15963. Epub 2019 May 30. PMID: 31148155; PMCID: PMC6771954. 4: Kleinman S, Stassinopoulos A. Transfusion-associated graft-versus-host disease reexamined: potential for improved prevention using a universally applied intervention. Transfusion. 2018 Nov;58(11):2545-2563. doi: 10.1111/trf.14930. Epub 2018 Sep 28. PMID: 30267423. 5: Brixner V, Kiessling AH, Madlener K, Müller MM, Leibacher J, Dombos S, Weber I, Pfeiffer HU, Geisen C, Schmidt M, Henschler R, North A, Huang N, Mufti N, Erickson A, Ernst C, Rico S, Benjamin RJ, Corash LM, Seifried E. Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery. Transfusion. 2018 Apr;58(4):905-916. doi: 10.1111/trf.14528. Epub 2018 Mar 1. PMID: 29498049. 6: Laughhunn A, Huang YS, Vanlandingham DL, Lanteri MC, Stassinopoulos A. Inactivation of chikungunya virus in blood components treated with amotosalen/ultraviolet A light or amustaline/glutathione. Transfusion. 2018 Mar;58(3):748-757. doi: 10.1111/trf.14442. Epub 2018 Jan 10. PMID: 29322519. 7: Aubry M, Laughhunn A, Santa Maria F, Lanteri MC, Stassinopoulos A, Musso D. Amustaline (S-303) treatment inactivates high levels of Chikungunya virus in red-blood-cell components. Vox Sang. 2018 Apr;113(3):232-241. doi: 10.1111/vox.12626. Epub 2018 Jan 4. PMID: 29314033. 8: Aubry M, Laughhunn A, Santa Maria F, Lanteri MC, Stassinopoulos A, Musso D. Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione. Transfusion. 2017 Dec;57(12):2888-2896. doi: 10.1111/trf.14318. Epub 2017 Sep 16. PMID: 28921542. 9: Tonnetti L, Laughhunn A, Thorp AM, Vasilyeva I, Dupuis K, Stassinopoulos A, Stramer SL. Inactivation of Babesia microti in red blood cells and platelet concentrates. Transfusion. 2017 Oct;57(10):2404-2412. doi: 10.1111/trf.14280. Epub 2017 Sep 5. PMID: 28872685. 10: Cancelas JA, Gottschall JL, Rugg N, Graminske S, Schott MA, North A, Huang N, Mufti N, Erickson A, Rico S, Corash L. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang. 2017 Apr;112(3):210-218. doi: 10.1111/vox.12500. Epub 2017 Feb 21. Erratum in: Vox Sang. 2017 Jul;112(5):495. PMID: 28220519. 11: Laughhunn A, Santa Maria F, Broult J, Lanteri MC, Stassinopoulos A, Musso D, Aubry M. Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components. Transfusion. 2017 Mar;57(3pt2):779-789. doi: 10.1111/trf.13993. Epub 2017 Feb 5. PMID: 28164306. 12: Wiltshire M, Meli A, Schott MA, Erickson A, Mufti N, Thomas S, Cardigan R. Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation. Transfus Med. 2016 Jun;26(3):208-14. doi: 10.1111/tme.12298. Epub 2016 Mar 23. PMID: 27006102. 13: Winter KM, Johnson L, Kwok M, Vidovic D, Hyland RA, Mufti N, Erickson A, Marks DC. Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment. Transfusion. 2014 Jul;54(7):1798-807. doi: 10.1111/trf.12545. Epub 2014 Mar 11. PMID: 24617658. 14: North A, Ciaravino V, Mufti N, Corash L. Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment. Transfusion. 2011 Oct;51(10):2208-18. doi: 10.1111/j.1537-2995.2011.03132.x. Epub 2011 Apr 19. PMID: 21985050. 15: Cancelas JA, Dumont LJ, Rugg N, Szczepiorkowski ZM, Herschel L, Siegel A, Pratt PG, Worsham DN, Erickson A, Propst M, North A, Sherman CD, Mufti NA, Reed WF, Corash L. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion. 2011 Nov;51(11):2367-76. doi: 10.1111/j.1537-2995.2011.03163.x. Epub 2011 May 13. PMID: 21569044. 16: Chakrabarty P, Rudra S, Hoque MM. Update of pathogen reduction technology for therapeutic plasma. Mymensingh Med J. 2010 Apr;19(2):308-11. PMID: 20395932. 17: Mufti NA, Erickson AC, North AK, Hanson D, Sawyer L, Corash LM, Lin L. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals. 2010 Jan;38(1):14-9. doi: 10.1016/j.biologicals.2009.10.019. Epub 2009 Dec 7. PMID: 19995680. 18: Rios JA, Hambleton J, Viele M, Rugg N, Sindermann G, Greenwalt T, Wages D, Cook D, Corash L. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion. 2006 Oct;46(10):1778-86. doi: 10.1111/j.1537-2995.2006.00973.x. PMID: 17002635. 19: Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, Wages D, Lin JS, Wood L, Corash L, Conlan MG. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion. 2005 Nov;45(11):1739-49. doi: 10.1111/j.1537-2995.2005.00583.x. PMID: 16271099.

View History

CL-2201

CL-2201